Day: October 26, 2022

On March 13, 2014, St. Laurent, Denis R.; Serrano-Wu, Michael H.; Belema, Makonen; Ding, Min; Fang, Hua; Gao, Min; Goodrich, Jason T.; Krause, Rudolph G.; Lemm, Julie A.; Liu, Mengping; Lopez, Omar D.; Nguyen, Van N.; Nower, Peter T.; O’Boyle, Donald R. II; Pearce, Bradley C.; Romine, Jeffrey L.; Valera, Lourdes; Sun, Jin-Hua; Wang, Ying-Kai; Yang, Fukang; Yang, Xuejie; Meanwell, Nicholas A.; Snyder, Lawrence B. published an article.Related Products of 1367744-24-8 The title of the article was HCV NS5A Replication Complex Inhibitors. Part 4. Optimization for Genotype 1a Replicon Inhibitory Activity. And the article contained the following:

Sym. stilbene bis(acylprolinamides) such as I (R = PhCH2, 2-EtC6H4, Ph, 2-vinylphenyl, 1-naphthyl, 3-ethyl-2-pyridinyl, 4-ethyl-2-pyridinyl, 3-vinyl-2-pyridinyl, 3-phenyl-2-pyridinyl, 1-isoquinolyl, 3-isoquinolinyl, 2-quinolinyl, 4-isoquinolinyl, 4-quinazolinyl, 1-phthalazinyl, 3-chloro-1-isoquinolinyl, 4-chloro-1-isoquinolinyl, 5-chloro-1-isoquinolinyl, 6-chloro-1-isoquinolinyl, 7-chloro-1-isoquinolinyl, 3-fluoro-1-isoquinolinyl, 5-fluoro-1-isoquinolinyl, 3-methyl-1-isoquinolinyl, 5-methyl-1-isoquinolinyl, 3-methoxy-5-isoquinolinyl, 5-methoxy-1-isoquinolinyl, 3-chloro-1-naphthyl, 3-chloro-5-fluoro-1-isoquinolinyl, 3-chloro-5-methoxy-1-isoquinolinyl, 5-methoxy-2-quinolinyl, 7-methoxy-2-quinolinyl) derived from the library-synthesized lead I (R = PhCH2) were prepared as HCV genotype 1a (G-1a) and genotype 1b (G-1b) replicon inhibitors; their selectivities for inhibition of HCV over general viral inhibition and their cytotoxicities to human Huh-7 cells were determined The structure-activity relationships for inhibition of HCV replication by sym. bis(prolinamide) HCV inhibitors were determined I (R = 1-isoquinolinyl) was a selective HCV NS5A inhibitor exhibiting submicromolar potency against both G-1a and G-1b replicons; further optimization identified I (R = 3-chloro-5-methoxy-1-isoquinolinyl) as a potent, dual G-1a/1b HCV NS5A inhibitor. The structure-activity relations derived from I were used in the discovery of the NS5A replication complex inhibitor daclatasvir II. The experimental process involved the reaction of 5-Methylisoquinoline-1-carbonitrile(cas: 1367744-24-8).Related Products of 1367744-24-8

The Article related to stilbene acylprolinamide preparation inhibition ns5a replication complex hepatitis c, structure bisacylprolinamide inhibition selectivity hepatitis c toxicity, hepatitis c genotype 1a replication inhibition stilbene acylprolinamide and other aspects.Related Products of 1367744-24-8

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On December 16, 2004, Yamada, Rintaro; Seto, Minoru published a patent.HPLC of Formula: 58142-46-4 The title of the patent was Preparation of diazaphenalene compounds as myosin-control light chains phosphorylation inhibitors. And the patent contained the following:

Title compounds I [R1 = H, chloro, OH; X1···X2 represents CH(R2)-CH(R3), etc.; R2, R3 = H, alkyl; A1, A11, A2, A21 = H, alkyl; Y = CH(A3), etc.; A3 = H, alkyl; Z = OH, etc.] were prepared For example, cyclization of compound II using potassium tert-butoxide followed by deprotection of tert-butoxycarbonyl group with HCl afforded compound III hydrochloride. In myosin regulatory light chains phosphorylation inhibition assays, the IC50 value of compound III·HCl was ≤10 μM. Compounds I are claimed to be useful for the treatment of glaucoma, bronchial asthma, etc. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).HPLC of Formula: 58142-46-4

The Article related to diazaphenalene preparation myosin regulatory light chain phosphorylation inhibitor, antiglaucoma diazaphenalene preparation myosin regulatory light chain phosphorylation inhibition, antiasthmatic diazaphenalene preparation myosin regulatory light chain phosphorylation inhibition and other aspects.HPLC of Formula: 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On February 5, 2004, Taveras, Arthur G.; Aki, Cynthia J.; Chao, Jianping; Dwyer, Michael; Chao, Jianhua; Yu, Younong; Merritt, J. Robert; Biju, Purakkattle; Jakway, James; Lai, Gaifa; Wu, Minglang; Hecker, Evan A.; Lundell, Daniel; Fine, Jay S. published a patent.Product Details of 74904-29-3 The title of the patent was Preparation of 3,4-di(substituted amino)cyclobutene-1,2-diones as CXC-chemokine receptor ligands. And the patent contained the following:

Disclosed are novel compounds of the formula (I) or pharmaceutically acceptable salts or solvates thereof [A = Q, Q1; B = substituted Ph, (un)substituted 1H-pyrazol-3-yl, 1H-pyrazol-5-yl, 2- or 3-thienyl, 1H-pyrrol-3-yl, 1H-pyrrol-2-yl, isothiazol-3-yl, 1,2-dihydro-4-hydroxy-2-oxo-pyridin-3-yl, 4-hydroxypyrimidin-4-yl, or 4-hydroxypyridin-3-yl, 1,2-dihydro-4-hydroxy-2-oxo-pyridin-5-yl, 1,4-dihydro-1-hydroxy-4-oxopyridin-2-yl, 1H-benzotriazol-7-yl, 1H-benzimidazol-7-yl, 1H-indol-7-yl, or benzo[c]pyrazol-7-yl; R7, R8 = H, each (un)substituted alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, CO2H, CONH2, alkynyl, alkenyl, cycloalkenyl; R12 = H,each (un)substituted CO2H, aryl, heteroaryl, arylalkyl, cycloalkyl, alkyl, cycloalkylalkyl, or heteroarylalkyl group]. Also disclosed is the treatment of chemokine-mediated diseases, where the chemokine binds to CXCR2 and/or CXCR1 receptor, using compounds of the formula I. The diseases include chronic inflammation, acute inflammatory pain, chronic inflammatory pain, acute neuropathic pain, chronic neuropathic pain, psoriasis, atopic dermatitis, asthma, COPD, adult respiratory disease, arthritis, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, septic shock, endotoxic shock, gram neg. sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulonephritis, thrombosis, Alzheimer’s disease, graft vs. host reaction, allograft rejections, malaria, acute respiratory distress syndrome, delayed type hypersensitivity reaction, atherosclerosis, cerebral and cardiac ischemia, osteoarthritis, multiple sclerosis, restenosis, angiogenesis, osteoporosis, gingivitis, respiratory viruses, herpes viruses, hepatitis viruses, HIV, Kaposi’s sarcoma associated virus, meningitis, cystic fibrosis, preterm labor, cough, pruritis, multiorgan dysfunction, trauma, strains, sprains, contusions, psoriatic arthritis, herpes, encephalitis, CNS vasculitis, traumatic brain injury, CNS tumors, and subarachnoid hemorrhage. They also include post surgical trauma, interstitial pneumonitis, hypersensitivity, crystal induced arthritis, acute and chronic pancreatitis, acute alc. hepatitis, necrotizing enterocolitis, chronic sinusitis, angiogenic ocular disease, ocular inflammation, retinopathy of prematurity, diabetic retinopathy, macular degeneration with the wet type preferred and corneal neovascularization, polymyositis, vasculitis, acne, gastric and duodenal ulcers, celiac disease, esophagitis, glossitis, airflow obstruction, airway hyperresponsiveness, bronchiectasis, bronchiolitis, bronchiolitis obliterans, chronic bronchitis, cor pulmonae, cough, dyspnea, emphysema, hypercapnea, hyperinflation, hypoxemia, hyperoxia-induced inflammations, hypoxia, surgical lung volume reduction, pulmonary fibrosis, pulmonary hypertension, right ventricular hypertrophy, peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD), granulocytic ehrlichiosis, sarcoidosis, small airway disease, ventilation-perfusion mismatching, wheeze, colds, gout, alc. liver disease, lupus, burn therapy, periodontitis, transplant reperfusion injury and early transplantation rejection, acute inflammation, and rheumatoid arthritis as well as cancer. The compounds I had IC50 of <10 μM for inhibiting the binding of [125I]-IL-8 to human chemokine receptor CXCR1. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Product Details of 74904-29-3

The Article related to aminocyclobutenedione preparation cxc chemokine receptor ligand, inflammation treatment aminocyclobutenedione preparation, inflammatory pain treatment aminocyclobutenedione preparation, cancer treatment aminocyclobutenedione preparation, psoriasis treatment aminocyclobutenedione preparation, atopic dermatitis treatment aminocyclobutenedione preparation and other aspects.Product Details of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On November 30, 2013, Abate, Carmen; Selivanova, Svetlana V.; Muller, Adrienne; Kramer, Stefanie D.; Schibli, Roger; Marottoli, Roberta; Perrone, Roberto; Berardi, Francesco; Niso, Mauro; Ametamey, Simon M. published an article.Related Products of 74904-29-3 The title of the article was Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the Positron Emission Tomography (PET) imaging of σ2 receptors. And the article contained the following:

σ2 Receptors are promising biomarkers for cancer diagnosis given the relationship between the proliferative status of tumors and their d. With the aim of contributing to the research of σ2 receptor Positron Emission Tomog. (PET) probes, we developed 2-[3-[6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]propyl]-3,4-dihydroisoquinolin-1(2H)-one (3), with optimal σ2 pharmacol. properties and appropriate lipophilicity. Hence, 3 served as the lead compound for the development of a series of dihydroisoquinolinones amenable to radiolabeling. Radiosynthesis for compound 26, which displayed the most appropriate σ2 profile, was developed and σ2 specific binding for the corresponding [18F]-26 was confirmed by in vitro autoradiog. on rat brain slices. Despite the excellent in vitro properties, [18F]-26 could not successfully image σ2 receptors in the rat brain in vivo, maybe because of its interaction with P-gp. Nevertheless, [18F]-26 may still be worthy of further investigation for the imaging of σ2 receptors in peripheral tumors devoid of P-gp overexpression. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Related Products of 74904-29-3

The Article related to brain, homo sapiens, human, positron emission tomography, tomography imaging agents, tumor imaging, σ1-non-opioid intracellular receptors role: bsu (biological study, unclassified), biol (biological study), σ2-non-opioid intracellular receptors role: bsu (biological study, unclassified), biol (biological study) and other aspects.Related Products of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem